Endometrial Cancer study: Hypo fractionated RT
Official title Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
ClinicalTrials.gov ID: NCT07871838
What this study is testing
- What it's testing
- This study aims to find out if a shorter radiation schedule is safe and how well it prevents cancer from returning. It also looks at how this treatment affects patients' overall health and quality of life.
- Who it's for
- The study is looking for women who have endometrial cancer.
- What's involved
- Participants will receive 5 radiation treatments over two weeks. They will also have regular blood tests, imaging scans, and fill out questionnaires to track their health.
- Time commitment
- The study lasts for 5 years, requiring 15 clinic visits for check-ups and monitoring.
- Time commitment: about 5 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Patients 18 years of age or older, ECOG 0-2.
- Newly diagnosed endometrial carcinoma, including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumours.
- FIGO 2009 stage I-IIIC1 are eligible. 20.
- Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be...
- Have an indication for adjuvant pelvic radiotherapy by the attending radiation oncology physician at tumour board discussion.
You likely can't join if
- ECOG 3 or higher.
- Para-aortic nodal disease.
- Non-standard surgery, evidence of residual disease after surgery.
- Need of a radiotherapy field exceeding the whole pelvis.
- Active inflammatory bowel disease.
- Active scleroderma.
See the full eligibility criteria
- Patients 18 years of age or older, ECOG 0-2.
- Newly diagnosed endometrial carcinoma, including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumours.
- FIGO 2009 stage I-IIIC1 are eligible. 20.
- Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be fully debulked (R0 resection).
- Have an indication for adjuvant pelvic radiotherapy by the attending radiation oncology physician at tumour board discussion.
- ECOG 3 or higher.
- Para-aortic nodal disease.
- Non-standard surgery, evidence of residual disease after surgery.
- Need of a radiotherapy field exceeding the whole pelvis.
- Active inflammatory bowel disease.
- Active scleroderma.
- Previous cancer in the last 5 years (except non-melanoma skin cancer).
- Patients with contraindication to CT contrast.
- Inability to achieve dose constraints.
- Inability to reproduce simulation positioning during treatment.
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 5 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.